Newton Charles W. 4

What Happened

• Charles W. Newton, a director of Novavax, received two equity awards on 2026-06-18: an option-style grant covering 21,270 derivative shares (reported at $0.00) and 14,180 restricted stock units (RSUs) (reported at $0.00), for a total of 35,450 shares subject to award. These were reported on a Form 4 filed 2026-06-23. The transaction codes are "A" (award/grant); no shares were sold or purchased for cash.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (appears to be one business day late vs. the 2-business-day rule).
• Pricing: $0.00 per share reported — indicates stock awards/grants, not open-market purchases.
• Shares after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: The 21,270-share option grant vests 100% on the first anniversary of the 6/18/2026 grant date, subject to continued Board service.
  • F2: Each RSU equals a contingent right to receive one share of Novavax common stock.
  • F3: The 14,180 RSUs vest 100% on the first anniversary of the 6/18/2026 grant date, subject to continued Board service.
• Transaction type: derivative awards (options/RSUs) — not an immediate sale or cash exercise.

Context

• These awards are compensatory grants that typically vest over time and are common for directors; they do not represent an immediate cash investment or sale. Options must be exercised and RSUs convert to shares only upon vesting and any applicable settlement. The late filing (filed 6/23 for 6/18 transaction) is procedural and may be subject to SEC reporting rules or company disclosure policies.